Evidence map›Paper›PMID 34187084›Full record

ArticleCancer science2021

NKG2D defines tumor-reacting effector CD8

Marija Mojic, Kiyomi Shitaoka, Chikako Ohshima, Sisca Ucche, Fulian Lyu, Hiroshi Hamana, Hideaki Tahara, Hiroyuki Kishi, Yoshihiro Hayakawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marija MojicInstitute of Natural Medicine, University of Toyama, Toyama, Japan.
Kiyomi ShitaokaDepartment of Immunology, Graduate School of Medicine and Pharmaceutical Sciences (Medicine), Toyama, Japan.
Chikako OhshimaInstitute of Natural Medicine, University of Toyama, Toyama, Japan.
Sisca UccheInstitute of Natural Medicine, University of Toyama, Toyama, Japan.
Fulian LyuDepartment of Immunology, Graduate School of Medicine and Pharmaceutical Sciences (Medicine), Toyama, Japan.
Hiroshi HamanaDepartment of Immunology, Graduate School of Medicine and Pharmaceutical Sciences (Medicine), Toyama, Japan.
Hideaki TaharaThe, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1735-5372
Hiroyuki KishiDepartment of Immunology, Graduate School of Medicine and Pharmaceutical Sciences (Medicine), Toyama, Japan.
Yoshihiro HayakawaInstitute of Natural Medicine, University of Toyama, Toyama, Japan.ORCID https://orcid.org/0000-0002-7921-1171
University of Toyama · JPTokyo Medical University · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 17H06398Yasuda Memorial Medical Foundation Research grant 2020
6 · The paper itself

Abstract

For successful immunotherapy for cancer, it is important to understand the immunological status of tumor antigen-specific CD8

Indexed as

AnimalsAntigens, NeoplasmAntimetabolites, AntineoplasticBromodeoxyuridineCD8-Positive T-LymphocytesInterferon-gammaLuciferasesLuminescent MeasurementsLymphocytes, Tumor-InfiltratingMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutNK Cell Lectin-Like Receptor Subfamily KOvalbuminSkin NeoplasmsAntigens, NeoplasmAntimetabolites, AntineoplasticBromodeoxyuridineIFNG protein, mouseInterferon-gammaKlrk1 protein, mouseLuciferasesNK Cell Lectin-Like Receptor Subfamily KOvalbumincytotoxic T cellimmune surveillanceNKG2DTOXtumor microenvironment

Identifiers

PMID34187084
PMCPMC8409295
OpenAlexW3177099890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.